Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Novartis Pharma Taking Steps to Protect Diovan's Sales, Share
July 17, 2006
- Ashitaba Powder Increases Bone Mass in Osteoporotic Rats: Takara Bio
July 17, 2006
- Taiho Licenses TS-1 to sanofi-aventis
July 17, 2006
- New Series：Drug Development Beyond Boundaries -Today's Global Cooperative Clinical Trials- Part I: Overview
July 17, 2006
- Takara Bio Licenses AML Testing Method to InVivo Scribe
July 17, 2006
- Kobayashi to Expand CHC Business
July 17, 2006
- Nihon Schering Ties Up with Daiichi Radioisotope
July 17, 2006
- ADR Offers New Method of Solving Patent Disputes
July 17, 2006
- BUSINESS NEWS IN BRIEF
July 17, 2006
- SEMINAR
July 17, 2006
- 116 Ingredients/402 Products Added in GE Drug Listing
July 17, 2006
- Taiyo Has Most GE Drugs Listed for 11th Year in a Row
July 17, 2006
- Most Generics Listed in 2006 Available in All Specifications
July 17, 2006
- Original Makers Preparing for Competition with Generics
July 17, 2006
- TOPICS 2 articles
July 17, 2006
- Marketing Companies Must Ally to Survive: Mr Eguchi
July 17, 2006
- Japan Exchanges Opinions with Chinese Regulatory Authorities
July 17, 2006
- Ain Pharmaciez Sets Up Generic Drug Wholesaler
July 17, 2006
- REGULATORY NEWS IN BRIEF
July 17, 2006
- PhRMA Applauds US Opposition for Annual NHI Price Revision
July 17, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…